Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow CLYM by emailGet an email when CLYM pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CLYM, unsubscribe in one click. Privacy
📣 What CLYM Says Is Next
in 2027 · “Initiation of Phase 3 registrational study anticipated in 2027 Webcast Information The live webcast is accessible via the “News & Events” section of the Climb Bio website: https://ir.climbbio.com/ .”
Company press release, Sep 3, 2026 · SEC filing
first half of 2027 · “Initial data from NAVIGATE-2 Phase 2 anticipated in the first half of 2027”
Company press release, Sep 3, 2026 · SEC filing
fourth quarter of 2026 · “Anticipate data, including safety and biomarker data from the Global study in the fourth quarter of 2026.”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full CLYM picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CLYM and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.